Boehringer Ingelheim Venture Fund co-led the oncology drug developer's series A round with Delos Capital and Xeraya Capital.
US-based cancer immunotherapy developer OncoMyx Therapeutics closed a $25m series A round yesterday co-led by Boehringer Ingelheim Venture Fund (BIVF), the corporate venturing vehicle for pharmaceutical firm Boehringer Ingelheim.
BIVF co-led the round with private equity firm Delos Capital and life sciences investment vehicle Xeraya Capital, while Korea Investment Partners, City Hill Ventures and Madison Partners also participated.
Founded in 2018, OncoMyx Therapeutics aims to exploit an oncolytic agent – a virus that selectively infects cancer cells – as the…
